Search

50% rise in number of women in UK who have not had vital breast screening since services restarted

The number of women in the UK who have not had vital NHS breast screening, which can stop people dying from breast cancer, has risen by an estimated 50% - to nearly 1.5 million women - since services resumed, the leading UK breast cancer charity has warned during Breast Cancer Awareness Month.  

Our researchers have discovered a new approach for treatment resistant breast cancers

At the Breast Cancer Now Research Unit at Kings College London, scientists have developed ‘triple engineered’ antibodies that can restrict the growth of aggressive and treatment-resistant breast cancers.

My first thoughts were, "How do I explain this to the girls?”

Julia, a mother to 2 young daughters, was diagnosed with Stage 2, Grade 3, HER2-positive breast cancer in April 2022 at the age of 41.

Understanding how some triple negative breast cancers spread to other parts of the body

Dr Sankari Nagarajan

Core competencies

Find out about opportunities to develop your skills and knowledge.

Our take on the new cancer roadmap

We take a detailed look at the strategy and outline the most important points.

My body confidence plummeted after having breast cancer, but now it’s better than ever before

When Cassie went through breast cancer treatment at 34, it changed how she felt about her body. She challenged herself to build back her confidence – and now she’s helping other people do the same.

It’s been difficult for us all, but we still talk about their mum every day

Martim’s wife, Celina, passed away in 2020, just one year after being diagnosed with secondary breast cancer. Suddenly a single dad to four young children, he had to find a way to adapt to his situation.

Finding new ways to boost the body's immune system for triple negative breast cancers

Dr John Maher

Investigating breast cancer health inequalities in Northern Ireland

Professor Chris Cardwell

Challenge terms and conditions

Talazoparib (Talzenna) approved for use on the NHS in Scotland

Responding to the decision by the Scottish Medicines Consortium (SMC) to recommend talazoparib (Talzenna) for use on the NHS in Scotland, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: